SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-266722
Filing Date
2022-10-21
Accepted
2022-10-21 16:05:56
Documents
12
Period of Report
2022-10-21
Items
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K d307901d8k.htm   iXBRL 8-K 27845
  Complete submission text file 0001193125-22-266722.txt   149655

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA urgn-20221021.xsd EX-101.SCH 2849
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE urgn-20221021_lab.xml EX-101.LAB 17996
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE urgn-20221021_pre.xml EX-101.PRE 11257
6 EXTRACTED XBRL INSTANCE DOCUMENT d307901d8k_htm.xml XML 3357
Mailing Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007
Business Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007 972 9 770 7601
UroGen Pharma Ltd. (Filer) CIK: 0001668243 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38079 | Film No.: 221323850
SIC: 2834 Pharmaceutical Preparations